Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GERN
GERN logo

GERN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Geron Corp (GERN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.490
1 Day change
5.67%
52 Week Range
2.010
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Geron Corp (GERN) is not a strong buy for a beginner investor with a long-term focus at this time. While hedge funds are increasing their positions and the company has shown slight improvements in revenue and net income, the stock's technical indicators are neutral, and there are no strong positive catalysts or proprietary trading signals to support an immediate buy decision. The recent price trend and lack of significant news or analyst upgrades also suggest a wait-and-see approach.

Technical Analysis

The MACD is below 0 and negatively contracting, RSI is neutral at 47, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 1.572, with resistance at 1.679 and support at 1.465.

Options Data

Bullish
Open Interest Put-Call Ratio
Neutral
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
6

Positive Catalysts

  • Hedge funds have significantly increased their buying activity by 226.92% over the last quarter.

Neutral/Negative Catalysts

  • No recent news or significant insider trading activity. Analyst price target was lowered from $4 to $3, and the stock has a 50% chance of declining in the short term based on candlestick analysis.

Financial Performance

In Q4 2025, revenue increased by 1.01% YoY to $48,015,000. Net income improved by 13.85% YoY but remains negative at -$28,862,000. EPS remained flat at -0.04, and gross margin slightly declined to 97.28%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

TD Cowen analyst maintained a Buy rating but lowered the price target from $4 to $3 ahead of Q4 results.

Wall Street analysts forecast GERN stock price to rise
4 Analyst Rating
Wall Street analysts forecast GERN stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.410
sliders
Low
4
Averages
4
High
4
Current: 1.410
sliders
Low
4
Averages
4
High
4
TD Cowen
Tara Bancroft
Buy
downgrade
$4 -> $3
AI Analysis
2026-01-29
Reason
TD Cowen
Tara Bancroft
Price Target
$4 -> $3
AI Analysis
2026-01-29
downgrade
Buy
Reason
TD Cowen analyst Tara Bancroft lowered the firm's price target on Geron to $3 from $4 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.
Goldman Sachs
initiated
$1
2025-07-10
Reason
Goldman Sachs
Price Target
$1
2025-07-10
initiated
Reason
Goldman Sachs resumed coverage of Geron with a Sell rating and $1 price target, which suggests 31% downside. The initial launch of the company's lead product and first commercial drug, Rytelo, has disappointed, and the near-term trajectory for the launch will be modest, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GERN
Unlock Now

People Also Watch